Researchers for GlaxoSmithKline and Synta Pharmaceuticals [1] say a mid-stage study of elesclomol [2] produced "statistically significant" data on progression-free survival of patients with metastatic melanoma.
"These data, combined with earlier clinical and pre-clinical data we have presented for elesclomol, support our belief that oxidative stress induction is a promising new approach to cancer therapy in melanoma and, potentially, other cancer types," said Eric Jacobson, M.D., Synta's CMO.
- here's the press release [3]
- read the AFX report [4]
Related Articles:
Synta outlines cash flow from Glaxo pact [5]
Synta scores $1.1B deal with GSK [1]
Synta therapy slows spread of melanoma [2]
Synta gets fast track for cancer therapy [6]
Links:
[1] http://www.fiercebiotech.com/story/synta-scores-1-1b-deal-gsk/2007-10-10
[2] http://www.fiercebiotech.com/story/synta-therapy-slows-spread-melanoma/2007-09-27
[3] http://www.fiercebiotech.com/press-releases/elesclomol-study-shows-significant-improvement-progression-free-survival-chemotherapy
[4] http://www.forbes.com/afxnewslimited/feeds/afx/2008/05/20/afx5029048.html
[5] http://www.fiercebiotech.com/story/synta-outlines-cash-flow-glaxo-pact/2007-11-13
[6] http://www.fiercebiotech.com/story/spotlight-synta-gets-fast-track-for-cancer-therapy/2006-11-15